Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Research Highlights
Nature Reviews Drug Discovery 7, 644–645 (1 August 2008) | doi:10.1038/nrd2644
Neurodegenerative diseases: Clearing up A|[beta]|
Abstract
The aggregation and deposition of amyloid-β (Aβ) peptides in the brain are thought to underlie the pathogenesis of Alzheimer's disease, and so therapeutic strategies to reduce Aβ levels are being intensively pursued. Two recent studies highlight how modulation of pathways involved in the regulation of Aβ levels can lead to enhanced degradation and clearance of Aβ from the brain.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
